Mindmed to host conference call and webcast to discuss data update for mm120

New york--(business wire)---- $mnmd--mind medicine (mindmed) inc. (nasdaq: mnmd), (cboe canada: mmed), (the "company" or "mindmed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a conference call and webcast on march 7, 2024. the program will provide an update on mm120 in generalized anxiety disorder (gad), including 12-week topline safety, efficacy, and durability results from the company's phase 2b tria.
MNMD Ratings Summary
MNMD Quant Ranking